| Starting Apr. 7, 2021, PharmaCare is switching coverage from patients taking originators adalimumab (Humira®) and etanercept (Enbrel®) to their biosimilars. adalimumab (Humira®) biosimilars: Amgevita® Hadlima®* Hulio® Hyrimoz®* Idacio® etanercept (Enbrel®) biosimilars: Brenzys® Erelzi® *Hadlima and Hyrimoz aren’t currently approved to treat pediatric Crohn’s disease Patients must meet with their prescriber to start the switching process. Between Apr. 7 and Oct. 7, both originator biologics and biosimilars will be covered by PharmaCare to assist the transition process. Starting on Oct. 7, coverage for the originators will cease and only the biosimilars will be covered. More information is available at www.gov.bc.ca/biosimilars/pharmacy |
